




FIG. 1A





FIG. 1A (Cont.)



IL-9

picograms per mg protein

Condition	Concentration (pg/mg protein)
PLC	~6
washed PLT	~3
PRP	~8

FIG. 1A (Cont.)




FIG. 1A (Cont.)

PLASMA-ASSOCIATED FACTORS

• PLC • washed PLT • PRP

(HIGH IN PRP BUT LOW/ABSENT IN PLC/PLT)




FIG. 1B

PLC-SPECIFIC FACTORS

• PLC • washed PLT • PRP

(HIGH IN PLC BUT LOW/ABSENT IN PLT AND PRP)




FIG. 1B (Cont.)




FIG. 1C




FIG. 1C (Cont.)




FIG. 1C (Cont.)




FIG. 2A




FIG. 2B




FIG. 2C





FIG. 2D

Vehicle



PRB v1 PLC




FIG. 2E

Figure 2 is a bar graph showing the change in CFS vs day 3 for various groups at Day 7, Day 10, and Day 14. The y-axis represents the change in CFS vs day 3, ranging from -2 to 4. The x-axis shows three time points: Day 7, Day 10, and Day 14. For each time point, there are seven groups: Untreated (n=20), Vehicle 150mM Trehalose (n=40), Restasis (n=20), PRB v1 PLC (n=40), PRB v2 MLC lysate matched, PRB v2 MLC lysate matched dose (n=20), and MLC Lysate max dose (n=20). Error bars represent standard error. Significance levels are indicated by asterisks: * p < 0.05, ** p < 0.01, *** p < 0.001. Brackets indicate significant differences between groups.

Time Point	Group	n	Change in CFS vs day 3 (approx.)	Significance
Day 7	Untreated	20	-1.2	***
	Vehicle 150mM Trehalose	40	-0.8	
	Restasis	20	-0.5	
	PRB v1 PLC	40	0.2	
	PRB v2 MLC lysate matched	20	1.8	
	PRB v2 MLC lysate matched dose	20	2.5	
	MLC Lysate max dose	20	3.2	
Day 10	Untreated	20	-1.2	***
	Vehicle 150mM Trehalose	40	-0.8	
	Restasis	20	-0.5	
	PRB v1 PLC	40	0.2	
	PRB v2 MLC lysate matched	20	1.8	
	PRB v2 MLC lysate matched dose	20	2.5	
	MLC Lysate max dose	20	3.2	
Day 14	Untreated	20	-1.2	***
	Vehicle 150mM Trehalose	40	-0.8	
	Restasis	20	-0.5	
	PRB v1 PLC	40	0.2	
	PRB v2 MLC lysate matched	20	1.8	
	PRB v2 MLC lysate matched dose	20	2.5	
	MLC Lysate max dose	20	3.2	




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 6C







FIG. 6D










FIG. 7D




FIG. 8A




FIG. 8B




FIG. 8C

PLCs vs. 20PCTE/5PCTE vs. 20PCTE/5PCTE/0.22PES vs. 200g vs. 21100g




FIG. 9A

1750-10000 nm particles




FIG. 9B




FIG. 10A




FIG. 10B




FIG. 11A






FIG. 11B






FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B




FIG. 13C

Histology of MMT joint (Day 28 post-surgery)

Vehicle

PLC treated





FIG. 13D

Substantial Cartilage Degeneration Width



= $P < 0.05$; *= $p < 0.001$

FIG. 13E




FIG. 13F




FIG. 13G




FIG. 14A




FIG. 14B




FIG. 15A






FIG. 15B








FIG. 15G




FIG. 15H




FIG. 16





FIG. 17A



BioR device schematic; top view on left, cross-section on right.

FIG. 17B